Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000075

Drug Information
NameCevimeline
SynonymsNCGC00181793-01; LS-145782; Spiro(1-azabicyclo(2.2.2)octane-3,5'-(1,3)-oxathiolane), 2'-methyl-, (2'R,3R)-rel-; Saligren (TN); (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]; HSDB 7286; Cevimeline hydrochloride hemihydrate; LS-172037; Cevimeline.HCl; AF 102B; (2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate; CID83927; Spiro(1-azabicyclo(2.2.2)octane-3,5'-(1,3)-oxathiolane), 2'-methyl-, cis-; 2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine; Cevimeline hydrochloride (USAN); SNI-2011; 153504-70-2; FKS-508; Cevimeline hydrochloride hydrate (JAN); SND 5008, AF-102B, FKS-508; AC1NR4MS; Fks 508; cevimeline hydrochloride hydrate; cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1); Saligren; Cevimeline (INN); AC1L36GD; Cevimeline hydrochloride [USAN]; UNII-P81Q6V85NP; BIDD:GT0265; Cevimeline; AF-102B; D00661; DB00185; Evoxac; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride; D07667; AC1OCEXD; UNII-K9V0CDQ56E; C10H17NOS; Evoxac (TN); (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride; CID83898; AC1L36EF; CID5284532; Cevimeline hydrochloride; CID6918023; AF102B; (+/-)cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate; Spiro(1-azabicyclo(2.2.2)octane-3,5'-(1,3)oxathiolane), 2'-methyl-, hydrochloride, hydrate (2:1), cis-; Cevimeline [INN]; (+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride; Cevimeline HCl 1/2H2O; 107233-08-9; SND-5008; SNK-508; CHEMBL1200362
Trade NameEvoxac
CompanyDaiichi Sankyo Pharma Development
IndicationSj?gren's syndrome
[ICD9: 710.2   ICD10: M35.0]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/2C10H17NOS.2ClH.H2O/c2*1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11;;
;/h2*8-9H,2-7H2,1H3;2*1H;1H2/t2*8-,10-;;;/m11.../s1
InChIKeyZSTLCHCDLIUXJE-GMLJRNIPSA-N
Canonical SMILESCC1OC2(CN3CCC2CC3)CS1.CC1OC2(CN3CCC2CC3)CS1.O.Cl.Cl    
Isomeric SMILESC[C@@H]1O[C@]2(CN3CCC2CC3)CS1.C[C@@H]1O[C@]2(CN3CCC2CC3)CS1.O.Cl.Cl
Therapeutic ClassParasympathomimetics
CAS NumberCAS 107233-08-9
FormulaC10H17NOS
PubChem Compound IDCID 83927.
PubChem Substance IDSID 660827.
ChEBI3568;
SuperDrug ATC IDN07AX03
N07AX03
TargetMuscarinic acetylcholine receptor M3Agonist[2]
Ref 1Therapeutic effect of cevimeline on dry eye in patients with Sj??gren's syndrome: a randomized, double-blind clinical study. Am J Ophthalmol. 2004 Jul;138(1):6-17. To Reference
Ref 2Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor agonist. Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G112-G123. Epub 2008 May 1. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543